September 22, 2008 - Early aggressive treatment with chemotherapy prior to radiotherapy may prolong survival for patients with anaplastic oligodendrogliomas according to new research from the Radiation Therapy Oncology Group (RTOG) presented at ASTRO 2008.

RTOG, an NCI-funded national clinical trials group, is a clinical research component of the American College of Radiology (ACR).

Longer-term results of an RTOG study show that administering chemotherapy prior to radiotherapy increased survival for oligodendroglioma patients. Progression-free survival also improved for those receiving the neoadjuvant chemotherapy, a benefit most evident in those whose tumors have deletions of chromosomes 1p and 19q.

“Our research, while providing some answers for patients with oligodendrogliomas, shows that longer follow-up and genetic profiles will be necessary to provide definitive answers for determining initial treatment strategies,” said Gregory Cairncross, M.D., of the University of Calgary Foothills Medical Centre in Calgary, Canada.

RTOG 9402, a phase III study, enrolled 299 anaplastic oligodendroglioma patients from July 1994 until March 2002 at 104 academic and community facilities in the U.S. and Canada. Patients were randomized to receive either standard radiotherapy alone or four cycles of neoadjuvant chemotherapy using procarbazine, lomustine, and vincristine followed by standard radiotherapy. The unadjusted estimated five-year overall survival rate for all patients entered on the study was slightly better for those who received neoadjuvant chemotherapy (49 vs. 46 percent). The adjusted five-year survival rate is significantly different favoring the experimental arm (hazard ratio = 0.66; 95 percent confidence interval (0.46, 0.95); p value = 0.02). For progression-free survival, the unadjusted estimated five-year rate for all patients entered on the study was significantly better for those who received neoadjuvant chemotherapy (37 vs. 22 percent; p value = 0.003). The adjusted five-year overall progression-free survival was also significantly different favoring the experimental arm (hazard ratio = 0.57; 95 percent confidence interval (0.41, 0.79); p value = 0.02).

Molecular analysis of oligodendrogliomas divides these tumors into two groups – those with deletion of both chromosomes 1p and 19q and those without. RTOG research has shown that patients with the deletions have a better response to treatment and overall survival. RTOG 9402 data reports that patients with the deletion had a median survival of 8.7 years vs. 2.7 years for those without the co-deletion (p

For more information: www.rtog.org, www.acr.org


Related Content

News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
Subscribe Now